CDK4/6 Inhibitors in Combination With Hormone Therapy for HR+/HER2− Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials-Reference-Cited by-同舟云学术

CDK4/6 Inhibitors in Combination With Hormone Therapy for HR+/HER2− Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Published:2018-10 Issue:5 Volume:18 Page:e943-e953
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Deng Yunfu,Ma Guangzhi,Li Wen,Wang Ting,Zhao Yaqin,Wu Qiang

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference35 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status;Howlader;J Natl Cancer Inst,2014

3. Araki K, Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. In press.

4. Novel strategies in hormone receptor–positive advanced breast cancer: overcoming endocrine resistance;Garrido-Castro;Curr Breast Cancer Rep,2016

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials;Frontiers in Pharmacology;2024-01-15

2. Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2− breast cancer: an umbrella review;Journal of Cancer Research and Clinical Oncology;2024-01

3. Risk of Cardiovascular Events with Cyclin-Dependent Kinases 4 and 6 (CDK 4/6) Inhibitors among Patients with Advanced Breast Cancer: A Systematic Review and Network Meta-Analysis;Reviews in Cardiovascular Medicine;2023-11-09

4. Novel CDK Inhibitors in Breast Cancer;Therapeutic potential of Cell Cycle Kinases in Breast Cancer;2023

5. Risk of Abemaciclib-induced Liver Injury in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer: A Retrospective Analysis;Anticancer Research;2022-12